tiprankstipranks
PCI Biotech Holding ASA (DE:4QG)
BERLIN:4QG

PCI Biotech Holding ASA (4QG) Income Statement

1 Followers

PCI Biotech Holding ASA Income Statement

Last quarter (Q3 2022), PCI Biotech Holding ASA's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q3, PCI Biotech Holding ASA's net income was kr-10.70M. See PCI Biotech Holding ASA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-kr 0.00kr 0.00kr 0.00-kr 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
kr 72.66Mkr 86.03Mkr 82.12Mkr 88.80Mkr 44.52Mkr 43.43M
Operating Income
kr -72.66Mkr -86.03Mkr -82.12Mkr -88.80Mkr -44.52Mkr -43.43M
Net Non Operating Interest Income Expense
kr -788.00Kkr -2.36Mkr 9.88Mkr 57.00Kkr 9.74Mkr 590.00K
Other Income Expense
------
Pretax Income
kr -73.45Mkr -88.39Mkr -72.24Mkr -88.75Mkr -34.78Mkr -42.84M
Tax Provision
-kr 0.00kr 0.00kr 0.00kr 0.00kr 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
kr -73.45Mkr -88.39Mkr -72.24Mkr -88.75Mkr -34.78Mkr -42.84M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
kr 72.66Mkr 86.03Mkr 82.12Mkr 88.80Mkr 44.52Mkr 43.43M
Net Income From Continuing And Discontinued Operation
kr -73.45Mkr -88.39Mkr -72.24Mkr -88.75Mkr -34.78Mkr -42.84M
Normalized Income
kr -73.45Mkr -88.39Mkr -72.24Mkr -88.75Mkr -34.78Mkr -42.84M
Interest Expense
kr -2.05Mkr 89.00Kkr 397.00Kkr 506.00Kkr 117.00Kkr 0.00
EBIT
kr -75.49Mkr -88.30Mkr -71.84Mkr -88.24Mkr -34.66Mkr -42.84M
EBITDA
kr -68.60Mkr -85.76Mkr -69.63Mkr -87.28Mkr -34.66Mkr -42.84M
Currency in NOK

PCI Biotech Holding ASA Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis